28.57
price down icon2.49%   -0.73
after-market Handel nachbörslich: 28.58 0.010 +0.04%
loading

Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten

pulisher
Mar 11, 2026

How Teva’s Blackstone-Backed ‘Pivot to Growth’ Strategy Could Reshape Teva Pharmaceutical Industries (TEVA) Investors - Sahm

Mar 11, 2026
pulisher
Mar 10, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Pivot To Growth Update At Leerink Conference - Sahm

Mar 10, 2026
pulisher
Mar 06, 2026

Teva Blackstone Duvakitug Deal Tests Growth Story And Concentration Risk - Sahm

Mar 06, 2026
pulisher
Mar 04, 2026

Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding - The Motley Fool

Mar 04, 2026
pulisher
Mar 03, 2026

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug - Sahm

Mar 03, 2026
pulisher
Mar 02, 2026

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong 1 Year Shareholder Returns - Sahm

Mar 02, 2026
pulisher
Mar 01, 2026

Duvakitug IBD Data and TEV-749 Filing Might Change The Case For Investing In Teva (TEVA) - Sahm

Mar 01, 2026
pulisher
Feb 28, 2026

Teva to Present at the Upcoming Investor Conferences in March - Sahm

Feb 28, 2026
pulisher
Feb 27, 2026

J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold? - Finviz

Feb 27, 2026
pulisher
Feb 26, 2026

Where is Teva Pharmaceutical Industries Limited (TEVA) Headed? - Finviz

Feb 26, 2026
pulisher
Feb 25, 2026

Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz

Feb 25, 2026
pulisher
Feb 23, 2026

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application - Sahm

Feb 23, 2026
pulisher
Feb 22, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Its Strong Recent Share Price Momentum - Sahm

Feb 22, 2026
pulisher
Feb 20, 2026

Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities - Finviz

Feb 20, 2026
pulisher
Feb 19, 2026

Corcept Therapeutics Stock Plunges As Court Clears Teva Generic - Sahm

Feb 19, 2026
pulisher
Feb 18, 2026

Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026 - Finviz

Feb 18, 2026
pulisher
Feb 18, 2026

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus

Feb 18, 2026
pulisher
Feb 18, 2026

Teva’s Duvakitug Data Puts Ulcerative Colitis And Crohn’s Bet In Focus - Sahm

Feb 18, 2026
pulisher
Feb 17, 2026

Should You Invest in Teva Pharmaceutical (TEVA), Here's What the Street Has to Say - Finviz

Feb 17, 2026
pulisher
Feb 12, 2026

Teva (TEVA) Is Down 5.2% After Returning To Profitability On Innovation-Led Revenue Shift – What’s Changed - Sahm

Feb 12, 2026
pulisher
Feb 10, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Valuation In Focus Amid Momentum - Kalkine Media

Feb 10, 2026
pulisher
Feb 10, 2026

Here's What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings - Finviz

Feb 10, 2026
pulisher
Feb 10, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes - Sahm

Feb 10, 2026
pulisher
Feb 09, 2026

A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings - Sahm

Feb 09, 2026
pulisher
Feb 04, 2026

Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat - Finviz

Feb 04, 2026
pulisher
Feb 04, 2026

Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Sahm

Feb 04, 2026
pulisher
Feb 04, 2026

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory - Finviz

Feb 04, 2026
pulisher
Feb 03, 2026

Teva Canada Mayzent Deal Supports Neuroscience Focus And Valuation Debate - Sahm

Feb 03, 2026
pulisher
Feb 03, 2026

FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Feb 03, 2026
pulisher
Feb 03, 2026

Earnings call transcript: Teva Q4 2025 earnings beat expectations, stock rises - Investing.com

Feb 03, 2026
pulisher
Feb 02, 2026

Assessing Teva Pharmaceutical Industries’ Valuation After Strong 2025 Earnings And Analyst Upgrades - Sahm

Feb 02, 2026
pulisher
Feb 01, 2026

Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress - Sahm

Feb 01, 2026
pulisher
Jan 31, 2026

Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds - Finviz

Jan 31, 2026
pulisher
Jan 31, 2026

Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis - Finviz

Jan 31, 2026
pulisher
Jan 30, 2026

Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge - Sahm

Jan 30, 2026
pulisher
Jan 30, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High Following Earnings Beat - Defense World

Jan 30, 2026
pulisher
Jan 29, 2026

Teva Balances Huntington’s Disease Outreach With Branded Drug Transformation - Sahm

Jan 29, 2026
pulisher
Jan 29, 2026

TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz

Jan 29, 2026
pulisher
Jan 29, 2026

What Makes Teva Pharmaceuticals (TEVA) a Successful Brand? - Finviz

Jan 29, 2026
pulisher
Jan 29, 2026

Teva Pharma stock hits 52-week high at 33.42 USD By Investing.com - Investing.com Nigeria

Jan 29, 2026
pulisher
Jan 29, 2026

Teva Pharma stock hits 52-week high at 33.42 USD - Investing.com

Jan 29, 2026
pulisher
Jan 28, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Margin Recovery Challenges High P/E Valuation Narrative - Sahm

Jan 28, 2026
pulisher
Jan 28, 2026

Teva To See Generics Loss From Revlimid in 2026, but Innovative Portfolio Drives Margin Expansion - morningstar.com

Jan 28, 2026
pulisher
Jan 28, 2026

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook - Sahm

Jan 28, 2026
pulisher
Jan 28, 2026

Earnings call transcript: Teva beats Q4 2025 EPS forecast, stock dips - Investing.com

Jan 28, 2026
$536.12
price up icon 0.62%
drug_manufacturers_specialty_generic HLN
$10.03
price down icon 0.40%
drug_manufacturers_specialty_generic ZTS
$115.62
price up icon 0.14%
$13.51
price down icon 2.10%
$129.78
price up icon 1.57%
Kapitalisierung:     |  Volumen (24h):